Can Reliance Market Its Biosimilar Drug TrastuRel? Supreme Court Says Yes

Introduction

The Supreme Court of India recently addressed a significant issue regarding the marketing of biosimilar drugs in the case of M/s Genentech Inc. & Ors. vs Drug Controller General of India & Ors. The court's ruling has implications for the pharmaceutical industry, particularly concerning the balance between patent rights and public health.

Case Background

The case arose from an appeal against an interim order of the Delhi High Court, which allowed M/s Reliance Life Sciences Pvt. Ltd. to market its biosimilar drug, TrastuRel, despite objections from M/s Genentech Inc. and its affiliates. Genentech claimed to be the innovator of the monoclonal antibody drug Trastuzumab, marketed under various brand names, including HERCEPTIN. The appellants sought to restrain Reliance from launching TrastuRel, arguing that it had not undergone the necessary testing and trials as required by the Drugs and Cosmetics Act, 1940.

The appellants contended that the approval granted to Reliance for TrastuRel was flawed, as it did not comply with the 2012 Guidelines for biosimilars. They argued that the drug had not been adequately tested for safety and efficacy, raising concerns about public health. The Delhi High Court had previously imposed conditions on the marketing of TrastuRel, which were challenged by Reliance.

What The Lower Authorities Held

The Delhi High Court's Division Bench had allowed Reliance to market TrastuRel, stating that the regulatory approval could not be deemed illegal at that stage. The court noted that the patent for Trastuzumab had expired in 2013, which raised questions about the appellants' standing to challenge the marketing of TrastuRel. The Division Bench observed that the appellants' suit could potentially stifle competition in the market.

The Single Judge had previously imposed conditions on Reliance's marketing of TrastuRel, including restrictions on labeling and advertising. However, the Division Bench's ruling effectively lifted these restrictions, allowing Reliance to market its product under certain conditions.

The Court's Reasoning

The Supreme Court, while reviewing the case, emphasized the importance of considering both parties' applications and appeals simultaneously, as directed in a previous order. The court found that the Division Bench had failed to do so, focusing solely on Reliance's application without adequately addressing the appellants' concerns.

The court noted that the interim order imposed by the Single Judge had been in effect for over three years, allowing Reliance to market TrastuRel under specific conditions. The Supreme Court held that the Division Bench's decision to lift these conditions without a thorough examination of the appellants' application was erroneous. The court underscored the need for a balanced approach, considering public health and safety while also respecting the rights of pharmaceutical innovators.

Statutory Interpretation

The ruling involved an interpretation of the Drugs and Cosmetics Act, 1940, particularly concerning the approval process for biosimilar drugs. The court highlighted the necessity for compliance with established guidelines and the importance of conducting appropriate clinical trials to ensure the safety and efficacy of biosimilars. The court's decision reinforced the principle that regulatory approvals must adhere to statutory requirements, even in the context of interim measures.

Constitutional or Policy Context

While the judgment did not delve deeply into constitutional issues, it touched upon the broader policy implications of drug regulation and public health. The court recognized the need to balance the interests of pharmaceutical companies with the imperative of ensuring safe and effective treatments for patients. This balance is crucial in the context of biosimilars, which can significantly impact healthcare access and affordability.

Why This Judgment Matters

This ruling is significant for several reasons. Firstly, it clarifies the legal landscape surrounding the marketing of biosimilars in India, particularly in relation to patent rights and regulatory compliance. The court's emphasis on the need for simultaneous consideration of applications ensures that both innovators and generic manufacturers have their rights and concerns addressed.

Secondly, the judgment underscores the importance of public health considerations in drug regulation. By allowing Reliance to market TrastuRel while maintaining certain conditions, the court recognized the need to ensure that patients have access to potentially life-saving treatments without compromising safety.

Finally, the ruling sets a precedent for future cases involving biosimilars and patent disputes, highlighting the need for careful scrutiny of regulatory approvals and the obligations of manufacturers to adhere to established guidelines.

Final Outcome

The Supreme Court set aside the impugned order of the Delhi High Court's Division Bench, reinstating the interim directions imposed by the Single Judge on 25.04.2016. The court requested the High Court to expedite the final disposal of the underlying suit while allowing Reliance to participate in government procurement for TrastuRel without impediment.

Case Details

• Case Title: M/s Genentech Inc. & Ors. vs Drug Controller General of India & Ors.
• Citation: 2019 INSC 1391
• Court: IN THE SUPREME COURT OF INDIA
• Bench: R.BANUMATHI, J. & A.S.BOPANNA, J. & HRISHIKESH ROY, J.
• Date of Judgment: 2019-12-17